Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
01:00pm, Wednesday, 16'th Aug 2023
Developmental biotechs can deliver outstanding returns for risk-tolerant investors. Wall Street is exceptionally bullish on Stoke Therapeutics, a clinical-stage company developing RNA-based medicines.
Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing
11:31am, Thursday, 10'th Aug 2023
After losing some value lately, a hammer chart pattern has been formed for Acadia (ACAD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
01:42pm, Wednesday, 09'th Aug 2023
FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up
09:48am, Thursday, 03'rd Aug 2023
Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
06:43pm, Wednesday, 02'nd Aug 2023
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to loss of $0.21 per share a year ag
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
02:28pm, Friday, 21'st Jul 2023
We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves
07:08am, Tuesday, 18'th Jul 2023
Shares of ACADIA Pharmaceuticals Inc. NASDAQ: ACAD jumped nearly 25% on Friday after the San Diego-based company announced preliminary second-quarter results and a pivotal acquisition. The gain was th
Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here's What to Expect.
10:20pm, Monday, 17'th Jul 2023
In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbre
Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?
04:32am, Monday, 17'th Jul 2023
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Why Acadia Pharmaceuticals Stock Is Soaring Today
11:41am, Friday, 14'th Jul 2023
Acadia has acquired expanded rights to two drugs. The company also provided encouraging preliminary Q2 sales figures for its two approved products.
Acadia (ACAD) Expands Existing Licensing Deal With Neuren
09:39am, Friday, 14'th Jul 2023
Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidat
Why These 2 Biotech Stocks Made Big Moves Late Thursday
07:11pm, Thursday, 13'th Jul 2023
Stock markets kept climbing on Thursday. Acadia stock moved higher as the company expanded a key licensing agreement.
Acadia Pharmaceuticals stock rockets 30% following expanded drug rights
04:40pm, Thursday, 13'th Jul 2023
Acadia Pharmaceuticals Inc. ACAD, -0.23% shares rallied in the extended session Thursday after the drug maker said it expanded its rights to a treatment for a rare neurological disorder. Acadia shares
Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS
10:27am, Wednesday, 14'th Jun 2023
Acadia (ACAD) is set to begin a pivotal study evaluating a new developmental candidate, ACP-101, in the treatment of hyperphagia associated with Prader-Willi syndrome.
Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue?
12:34pm, Wednesday, 07'th Jun 2023
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
